Imugene Limited (IMU.XA)
| Previous close | 0.1100 |
| Open | 0.1150 |
| Bid | 0.1000 x N/A |
| Ask | 0.1200 x N/A |
| Day's range | 0.1000 - 0.1150 |
| 52-week range | 0.0390 - 0.1950 |
| Volume | |
| Avg. volume | 27,909,240 |
| Market cap | N/A |
| Beta (5Y monthly) | 2.54 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0050 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.While Imugene (ASX:IMU) shareholders have made 304% in 5 years, increasing losses might now be front of mind as stock sheds 12% this week
The Imugene Limited ( ASX:IMU ) share price has had a bad week, falling 12%. But that doesn't change the fact that the...
- Business Wire
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform
LOS ALTOS, Calif. & SYDNEY, July 20, 2023--RenovoRx, Inc. ("RenovoRx") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, and Imugene Ltd ("Imugene") (ASX: IMU), a clinical-stage immuno-oncology company, today announced a strategic research collaboration to optimize the delivery of Imugene’s oncolytic virus therapy with RenovoRx’s TAMP (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of difficult-to-access tumors.
GlobeNewswireKineta Expands Board of Directors with Biotech Industry Leaders Kim Drapkin and Scott Dylla
SEATTLE, June 28, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today the appointment of Kim Drapkin and Scott Dylla, Ph.D. to its Board of Directors. Ms. Drapkin will join the company’s audit and compensation committees and Dr. Dylla will join the compensation committee. “Kim and Scott’s extensive strategic, financial and clinical expertis
